Alynx, Company (AYXC.OB) announced that the company has completed their acquisition of 100% of the outstanding shares of MiMedx, Inc. – a development-stage medical device company, based in Tampa, Florida.
Subsequent to this transaction, Alynx has issued approximately 52.9 million new shares of common stock and approximately 3.7 million new shares of their preferred stock. Furthermore, Alynx repurchased and canceled 20.0 million shares of their outstanding common stock. The shares issued in the merger were issued pursuant to a private placement and are not presently eligible for resale to the public.
Lastly, the executive officers and directors of MiMedx have replaced the officers and directors of Alynx. The new board of directs have expressed interest in a reverse stock split of all common stock, resulting in a one-for-three share deal. This stock split will also reduce the total shares outstanding to approximately 36.5 million shares.
Let us hear your thoughts below:
